alpha-MSH raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-11-26 and is reviewed periodically as new material appears.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic cyclic heptapeptide | Analog of alpha-MSH with an internal lactam bridge |
| Molecular weight | Approximately 1024 daltons | Free base value; salt forms differ |
| Appearance | White to off-white powder | Usually supplied as a lyophilized solid |
| Solubility | Freely soluble in water | Poorly soluble in nonpolar solvents |
| Typical storage | −20 °C, dry, protected from light | Repeated freeze-thaw cycles degrade peptides |
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
13 November – Sir Donald McIntyre, operatic bass-baritone, Grammy winner (1983), Arts Foundation of New Zealand Icon (since 2004) (born 1934). 14 November – June Slee, educationist (Charles Darwin University), writer, and local politician, Canterbury Regional Councillor (2004–2007), Waitaki District Councillor (2013–2016) (born 1945). 15 November John Keoghan, agricultural scientist (University of the West Indies, AgResearch) and conservationist (born 1942). Derek Leask, diplomat, High Commissioner to the United Kingdom (2008–2013) (born 1948). 16 November Monty Knight, businessman, viticulturist, and local politician, Far North District Councillor (2010–2013), Northland Regional Councillor (2015–2016) (born 1945). Dennis Pezaro, general practitioner, chair of the New Zealand Medical Association (1994–1996) (born 1942). Ian Therkleson, cricketer (Wellington) (born 1938). 17 November – John Husband, artist and talkback radio host (Foveaux Radio) (born 1930). 21 November Grant Arkell, boxing trainer (Joseph Parker, Patrick Mailata, Mose Auimatagi Jnr) (born c. 1948). Costa Botes, film and documentary maker (Forgotten Silver, Saving Grace, Candyman), Qantas Film and Television Award for best popular documentary (2010) (born 1958). 23 November – Alistar Jordan, cricketer (Central Districts, Cambridgeshire) (born 1949). 27 November – Ian Hampton, cricketer (Central Districts) (born 1942). 30 November – Kevin Brown, local politician, Mayor of Grey (1998–2004) (born 1935).
Bipolar cell A type of amacrine cell that transmits signals from photoreceptors (rods and cones) to ganglion cells in the eye, playing a key role in visual processing. Bipolar disorder A mood disorder characterized by alternating episodes of depression and mania, associated with dysregulation in neurotransmitter systems and structural brain changes. Blood–brain barrier (BBB) A selective barrier formed by endothelial cells lining brain capillaries that restricts the passage of substances from the bloodstream into the central nervous system, protecting the brain from pathogens and toxins. Bouton Also known as an axon terminal or synaptic bouton, this is the swollen end of an axon where neurotransmitters are released into the synaptic cleft. Brain The central organ of the nervous system, responsible for processing sensory information, regulating bodily functions, and enabling thought, emotion, memory, and consciousness. Brain-derived neurotrophic factor (BDNF) A protein that supports the survival of existing neurons and encourages the growth and differentiation of new neurons and synapses. It is crucial for long-term memory and synaptic plasticity. Brain plasticity Also called neuroplasticity, this refers to the brain’s ability to reorganize and adapt by forming new neural connections throughout life, especially after injury or in response to learning and experience. Brainstem The posterior part of the brain that connects the cerebrum with the spinal cord.
9 November – Buckingham Palace announces that Queen Camilla will miss Remembrance events held over the weekend as she recovers from a chest infection. 10 November – First Minister of Northern Ireland Michelle O'Neill becomes the first senior Sinn Féin figure to take part in an official Remembrance Sunday ceremony, held in Belfast. 11 November The Terminally Ill Adults (End of Life) Bill, which would allow terminally ill people in England and Wales with less than six months to live to seek assistance in ending their lives, with the consent of two doctors and a High Court judge, is published. Helen-Ann Hartley, the Bishop of Newcastle, calls for Justin Welby to resign as the Archbishop of Canterbury following a damning report into prolific child abuser John Smyth QC, who was associated with the Church of England. At the Old Bailey, former soldier Daniel Khalife changes his plea midway through his trial, and pleads guilty to escaping from prison in September 2023. His trial on three other charges continues. At the invitation of French President Emmanuel Macron, Starmer travels to France to mark Armistice Day at the Tomb of the Unknown Soldier, then holds talks with Macron to affirm the UK and France's commitment to supporting Ukraine. 12 November The BBC confirms that Gary Lineker will step down as Match of the Day presenter at the end of the current season, but will host BBC Sport's coverage of the 2026 World Cup.
== Evolution == Some 23-million-year-old fossils of arapaima or a very similar species have been found in the Miocene Villavieja Formation of Colombia. Museum specimens are found in France, England, the United States, Brazil, Guyana, Ecuador and Perú. This makes them some of the oldest known species of freshwater fish.
Sources: en.wikipedia.org
=== Exercise === Horses with PSSM show fewer clinical signs if their exercise is slowly increased over time (i.e. they are slowly conditioned). Additionally, they are much more likely to develop muscle stiffness and rhabdomyolysis if they are exercised after prolonged stall rest. Horses generally have fewer clinical signs when asked to perform short bouts of work at maximal activity level (anaerobic exercise), although they have difficulty achieving maximal speed and tire faster than unaffected horses. They have more muscle damage when asked to perform lower intensity activity over a longer period of time (aerobic activity), due to an energy deficit in the muscle.
The Court of Justice, repeating its view in Van Gend en Loos, said member states "have limited their sovereign rights, albeit within limited fields, and have thus created a body of law which binds both their nationals and themselves" on the "basis of reciprocity". EU law would not "be overridden by domestic legal provisions, however framed... without the legal basis of the community itself being called into question". This meant any "subsequent unilateral act" of the member state inapplicable. Similarly, in Amministrazione delle Finanze dello Stato v Simmenthal SpA, a company, Simmenthal SpA, claimed that a public health inspection fee under an Italian law of 1970 for importing beef from France to Italy was contrary to two Regulations from 1964 and 1968. In "accordance with the principle of the precedence of Community law", said the Court of Justice, the "directly applicable measures of the institutions" (such as the Regulations in the case) "render automatically inapplicable any conflicting provision of current national law". This was necessary to prevent a "corresponding denial" of Treaty "obligations undertaken unconditionally and irrevocably by member states", that could "imperil the very foundations of the" EU. But despite the views of the Court of Justice, the national courts of member states have not accepted the same analysis.
Extrapyramidal signs Rhabdomyolysis, acute Ataxia Irregular heart beat Mild hypothyroidism Loss of milestones Delayed speech and language acquisition Delayed walking Abnormal liver enzymes Gastrointestinal dysmotility Generalised brain atrophy High blood ammonia levels Low blood sugar Involuntary muscle contractions Increased lactate in body Prolonged QT interval Seizure Occasional:
KN035 is the only PD-L1 antibody with subcutaneous formulation currently under clinical evaluations in the US, China, and Japan AUNP12 is a 29-mer peptide as the first peptic PD-1/PD-L1 inhibitor developed by Aurigene and Laboratoires Pierre Fabre that is being evaluated in clinical trial, following promising in vitro results. CA-170, discovered by Aurigene/Curis as the PD-L1 and VISTA antagonist, was indicted as a potent small molecule inhibitor in vitro. Thus, the compound is currently under phase I clinical trial over mesothelioma patients. BMS-986189 is a macrocyclic peptide discovered by Bristol-Myers Squibb of which the pharmacokinetics, safety and tolerability is currently being studied on healthy subjects. INCB086550 is a small-molecule PD-L1 inhibitor.
== See also == History of atomic theory History of molecular theory History of crystallography before X-rays Geometrical crystallography before X-rays Physical crystallography before X-rays Timeline of chemistry Timeline of crystallography
Sources: en.wikipedia.org
It is a synthetic seven-amino-acid peptide modeled on alpha-melanocyte-stimulating hormone. It carries two non-natural substitutions and a cyclic bridge that increase its stability relative to the natural hormone. It circulates as a research chemical and is not an approved medicine.
Melanotan-1, also called afamelanotide, is a shorter linear analog with a different amino acid sequence and no lactam ring. It has been evaluated in formal clinical programs, while melanotan-2 has not. The two are distinct molecules and are not interchangeable.
No. Bremelanotide is a related but distinct cyclic peptide that reached approved status for one specific clinical indication. Melanotan-2 is a separate molecule with its own sequence and properties. Shared ancestry in the melanocortin family does not make them the same substance.
No regulatory agency has authorised melanotan-2 as a medicine for any indication. It circulates mainly as a research chemical or through unregulated channels. As a result, identity, purity and content are not independently guaranteed.